The oxidative modification hypothesis of atherogenesis: An overview

Free Radical Biology and Medicine

Volumn 28, Issue 12, 2000, Pages 1815-1826

  Chisolm, Guy M ^a   Steinberg, Daniel ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Atherosclerosis; Free radicals; Oxidized LDL; Scavenger receptors

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARACHIDONATE 15 LIPOXYGENASE; ASCORBIC ACID; BETA CAROTENE; CRESOL; FREE RADICAL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; N,N' DIPHENYLPHENYLENEDIAMINE; PROBUCOL; SCAVENGER RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; HYPOTHESIS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 0034659148     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(00)00344-0     Document Type: Article

References (134)

1. Hessler J.R., Robertson A.L. Jr, Chisolm G.M. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 32:1979;213-229.
2. Hessler J.R., Morel D.W., Lewis L.J., Chisolm G.M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 3:1983;215-222.
3. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J. Lipid Res. 24:1983;1070-1076.
4. Morel D.W., DiCorleto P.E., Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:1984;357-364.
5. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells recognition by receptors for acetylated low density lipoproteins . Proc. Natl. Acad. Sci. USA. 78:1981;6499-6503.
6. Henriksen T., Mahoney E.M., Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis. 3:1983;149-159.
7. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81:1984;3883-3887.
8. Hazen S.L. Oxidation and atherosclerosis. Free Radic. Biol. Med. 28:2000;1683-1684.
9. Berliner J., Leitinger N., Watson A., Huber J., Fogelman A., Navab M. Oxidized lipids in atherogenesis formation, destruction and action . Thromb. Haemost. 78:1997;195-199.
10. Negre-Salvayre A., Lopez M., Levade T., Pieraggi M.T., Dousset N., Douste-Blazy L., Salvayre R. Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. II. Uptake and cytotoxicity of ultraviolet-treated LDL on lymphoid cell lines. Biochim. Biophys. Acta. 1045:1990;224-232.
11. Steinberg D. Oxidized low density lipoprotein - an extreme example of lipoprotein heterogeneity. Isr. J. Med. Sci. 32:1996;469-472.
12. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28:2000;1708-1716.
13. Podrez, E. A.; Abu-Soud, H. M.; Hazen, S. L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic. Biol. Med. 28:1717-1725; 2000
14. Meagher E.A., FitzGerald G.A. Indices of lipid peroxidation in vivo strengths and limitations . Free Radic. Biol. Med. 28:2000;1745-1750.
15. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 28:2000;1685-1696.
16. Subbanagounder G., Watson A.D., Berliner J.A. Bioactive products of phospholipid oxidation isolation, identification, measurement and activities . Free Radic. Biol. Med. 28:2000;1751-1761.
17. Marathe G.K., Harrison K.A., Murphy R.C., Prescott S.M., Zimmerman G.A., McIntyre T.M. Bioactive phospholipid oxidation products. Free Radic. Biol. Med. 28:2000;1762-1770.
18. Yla-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
19. Palinski W., Rosenfeld M.E., Yla-Herttuala S., Gurtner G.C., Socher S.S., Butler S.W., Parthasarathy S., Carew T.E., Steinberg D., Witztum J.L. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1989;1372-1376.
20. Haberland M.E., Fong D., Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241:1988;215-218.
21. O'Brien K.D., Alpers C.E., Hokanson J.E., Wang S., Chait A. Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. Circulation. 94:1996;1216-1225.
22. Uchida K., Itakura K., Kawakishi S., Hiai H., Toyokuni S., Stadtman E.R. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch. Biochem. Biophys. 324:1995;241-248.
23. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum . Arterioscler. Thromb. 14:1994;605-616.
24. Jurgens G., Chen Q., Esterbauer H., Mair S., Ledinski G., Dinges H.P. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler. Thromb. 13:1993;1689-1699.
25. Rosenfeld M.E., Khoo J.C., Miller E., Parthasarathy S., Palinski W., Witztum J.L. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation-specific lipid-protein adducts. J. Clin. Invest. 87:1991;90-99.
26. Chang M.K., Bergmark C., Laurila A., Horkko S., Han K.H., Friedman P., Dennis E.A., Witztum J.L. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages evidence that oxidation-specific epitopes mediate macrophage recognition . Proc. Natl. Acad. Sci USA. 96:1999;6353-6358.
27. Watson A.D., Subbanagounder G., Welsbie D.S., Faull K.F., Navab M., Jung M.E., Fogelman A.M., Berliner J.A. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J. Biol. Chem. 274:1999;24787-24798.
28. Geng Y.J., Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am. J. Pathol. 147:1995;251-266.
29. Isner J.M., Kearney M., Bortman S., Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 91:1995;2703-2711.
30. Avogaro P., Bon G.B., Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 8:1988;79-87.
31. Hodis H.N., Kramsch D.M., Avogaro P., Bittolo-Bon G., Cazzolato G., Hwang J., Peterson H., Sevanian A. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J. Lipid Res. 35:1994;669-677.
32. Sevanian A., Bittolo-Bon G., Cazzolato G., Hodis H., Hwang J., Zamburlini A., Maiorino M., Ursini F. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J. Lipid Res. 38:1997;419-428.
33. Hörkkö S., Binder C.J., Shaw P.X., Chang M., Silverman G., Palinski W., Witztum J. Immunological responses to oxidized LDL. Free Radic. Biol. Med. 28:2000;1771-1779.
34. Navab M., Fogelman A.M., Berliner J.A., Territo M.C., Demer L.L., Frank J.S., Watson A.D., Edwards P.A., Lusis A.J. Pathogenesis of atherosclerosis. Am. J. Cardiol. 76:1995;18C-23C.
35. Chisolm G.M., Penn M.S. Oxidized lipoproteins and atherosclerosis. Fuster V., Ross R., Topol E.J. Atherosclerosis and coronary artery disease. 1996;129-149 Raven Press, New York.
36. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:1997;20963-20966.
37. Chisolm G.M. III, Chai Y.-C. Regulation of cell growth by oxidized LDL. Free Radic. Biol. Med. 28:2000;1697-1707.
38. Carr A., Frei B. The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic. Biol. Med. 28:2000;1806-1814.
39. Fox P.L., Chisolm G.M., DiCorleto P.E. Lipoprotein-mediated inhibition of endothelial cell production of platelet-derived growth factor-like protein depends on free radical lipid peroxidation. J. Biol. Chem. 262:1987;6046-6054.
40. Chisolm G.M. Cytotoxicity of oxidized lipoproteins. Curr. Opin. Lipidol. 2:1991;311-316.
41. Jurgens G., Hoff H.F., Chisolm G.M. III, Esterbauer H. Modification of human serum low density lipoprotein by oxidation - characterization and pathophysiological implications. Chem. Phys. Lipids. 45:1987;315-336.
42. Chisolm G.M., Ma G., Irwin K.C., Martin L.L., Gunderson K.G., Linberg L.F., Morel D.W., DiCorleto P.E. 7 beta-hydroperoxycholest-5-en-3 beta-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc. Natl. Acad. Sci. USA. 91:1994;11452-11456.
43. Hughes H., Mathews B., Lenz M.L., Guyton J.R. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler. Thromb. 14:1994;1177-1185.
44. Sevanian A., Hodis H.N., Hwang J., McLeod L.L., Peterson H. Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL. J. Lipid Res. 36:1995;1971-1986.
45. Colles S.M., Irwin K.C., Chisolm G.M. Roles of multiple oxidized LDL lipids in cellular injury dominance of 7 beta-hydroperoxycholesterol . J. Lipid Res. 37:1996;2018-2028.
46. Coffey M.D., Cole R.A., Colles S.M., Chisolm G.M. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals. J. Clin. Invest. 96:1995;1866-1873.
47. Thomas J.P., Geiger P.G., Girotti A.W. Lethal damage to endothelial cells by oxidized low density lipoprotein role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions . J. Lipid Res. 34:1993;479-490.
48. Lizard G., Monier S., Cordelet C., Gesquiere L., Deckert V., Gueldry S., Lagrost L., Gambert P. Characterization and comparison of the mode of cell death, apoptosis versus necrosis, induced by 7beta-hydroxycholesterol and 7-ketocholesterol in the cells of the vascular wall. Arterioscler. Thromb. Vasc. Biol. 19:1999;1190-1200.
49. Brown A.J., Leong S.L., Dean R.T., Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J. Lipid Res. 38:1997;1730-1745.
50. Morel D.W., Chisolm G.M. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J. Lipid Res. 30:1989;1827-1834.
51. Rangaswamy S., Penn M.S., Saidel G.M., Chisolm G.M. Exogenous oxidized low-density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circ. Res. 80:1997;37-44.
52. Rong J.X., Rangaswamy S., Shen L., Dave R., Chang Y.H., Peterson H., Hodis H.N., Chisolm G.M., Sevanian A. Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation. Arterioscler. Thromb. Vasc. Biol. 18:1998;1885-1894.
53. Steinberg D., Lewis A. Conner memorial lecture. Oxidative modification of LDL and atherogenesis. Circulation. 95:1997;1062-1071.
54. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv. Exp. Med. Biol. 369:1995;39-48.
55. Steinberg D. Antioxidants and atherosclerosis. A current assessment [editorial]. Circulation. 84:1991;1420-1425.
56. Chisolm G.M. III. Antioxidants and atherosclerosis a current assessment . Clin. Cardiol. 14:1991;I25-I30.
57. Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr. Opin. Lipidol. 10:1999;589-597.
58. Heinecke J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis implications for the oxidized low density lipoprotein hypothesis . Atherosclerosis. 141:1998;1-15.
59. Sevanian A., Hodis H. Antioxidants and atherosclerosis an overview . Biofactors. 6:1997;385-390.
60. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Jr. Antioxidants and atherosclerotic heart disease. N. Engl. J. Med. 337:1997;408-416.
61. Zhang S.H., Reddick R.L., Avdievich E., Surles L.K., Jones R.G., Reynolds J.B., Quarfordt S.H., Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99:1997;2858-2866.
62. Bird D.A., Tangirala R.K., Fruebis J., Steinberg D., Witztum J.L., Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. 39:1998;1079-1090.
63. Moghadasian M.H., McManus B.M., Godin D.V., Rodrigues B. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice possible mechanisms of action . Circulation. 99:1999;1733-1739.
64. Tangirala R.K., Casanada F., Miller E., Witztum J.L., Steinberg D., Palinski W. Effect of the antioxidant N,N′-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 15:1995;1625-1630.
65. Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. 4:1998;1189-1192.
66. Crawford R.S., Kirk E.A., Rosenfeld M.E., LeBoeuf R.C., Chait A. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18:1998;1506-1513.
67. Cynshi O., Kawabe Y., Suzuki T., Takashima Y., Kaise H., Nakamura M., Ohba Y., Kato Y., Tamura K., Hayasaka A., Higashida A., Sakaguchi H., Takeya M., Takahashi K., Inoue K., Noguchi N., Niki E., Kodama T. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc. Natl. Acad. Sci. USA. 95:1998;10123-10128.
68. Witting P.K., Pettersson K., Ostlund-Lindqvist A.M., Westerlund C., Eriksson A.W., Stocker R. Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J. 13:1999;667-675.
69. Fruebis J., Steinberg D., Dresel H.A., Carew T.E. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J. Clin. Invest. 94:1994;392-398.
70. Keaney J.F. Jr, Gaziano J.M., Xu A., Frei B., Curran-Celentano J., Shwaery G.T., Loscalzo J., Vita J.A. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc. Natl. Acad. Sci. USA. 90:1993;11880-11884.
71. Shaish A., Daugherty A., O'Sullivan F., Schonfeld G., Heinecke J.W. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J. Clin. Invest. 96:1995;2075-2082.
72. Kleinveld H.A., Demacker P.N., Stalenhoef A.F. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. 14:1994;1386-1391.
73. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T., Takashima Y., Kawabe Y., Cynshi O., Wada Y., Honda M., Kurihara H., Aburatani H., Doi T., Matsumoto A., Azuma S., Noda T., Toyoda Y., Itakura H., Yazaki Y., Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:1997;292-296.
74. Palkama T., Majuri M.L., Mattila P., Hurme M., Renkonen R. Regulation of endothelial adhesion molecules by ligands binding to the scavenger receptor. Clin. Exp. Immunol. 92:1993;353-360.
75. Haworth R., Platt N., Keshav S., Hughes D., Darley E., Suzuki H., Kurihara Y., Kodama T., Gordon S. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J. Exp. Med. 186:1997;1431-1439.
76. de Winther M.P., Gijbels M.J., van Dijk K.W., van Gorp P.J., Suzuki H., Kodama T., Frants R.R., Havekes L.M., Hofker M.H. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis. 144:1999;315-321.
77. Sakaguchi H., Takeya M., Suzuki H., Hakamata H., Kodama T., Horiuchi S., Gordon S., van der Laan L.J., Kraal G., Ishibashi S., Kitamura N., Takahashi K. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab. Invest. 78:1998;423-434.
78. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., Silverstein R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:2000;1049-1056.
79. de Winther M.P., Hofker M.H. Scavenging new insights into atherogenesis. J. Clin. Invest. 105:2000;1039-1041.
80. Conrad D.J. The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. Clin. Rev. Allergy Immunol. 17:1999;71-89.
81. Cathcart M.K., Folcik V.A. Lipoxygenases and atherosclerosis protections versus pathogenesis . Free Radic. Biol. Med. 28:2000;1726-1734.
82. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J. Clin. Invest. 103:1999;1487-1488.
83. Feinmark S.J., Cornicelli J.A. Is there a role for 15-lipoxygenase in atherogenesis? Biochem. Pharmacol. 54:1997;953-959.
84. Sigal E., Laughton C.W., Mulkins M.A. Oxidation, lipoxygenase, and atherogenesis. Ann. NY Acad. Sci. 714:1994;211-224.
85. Cyrus T., Witztum J.L., Rader D.J., Tangirala R., Fazio S., Linton M.F., Funk C.D. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J. Clin. Invest. 103:1999;1597-1604.
86. Bocan, T. M.; Rosebury, W. S.; Mueller, S. B.; Kuchera, S.; Welch, K.; Daugherty, A.; Cornicelli, J. A. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit [published erratum appears in Atherosclerosis 139:201; 1998]. Atherosclerosis 136:203-216; 1998.
87. Bocan, T. M.; Rosebury, W. S.; Mueller, S. B.; Kuchera, S.; Welch, K.; Daugherty, A.; Cornicelli, J. A. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit [published erratum appears in Atherosclerosis 139:201; 1998]. Atherosclerosis 136:203-216; 1998.
88. Shen J., Herderick E., Cornhill J.F., Zsigmond E., Kim H.S., Kuhn H., Guevara N.V., Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. 98:1996;2201-2208.
89. Chisolm G.M. III, Hazen S.L., Fox P.L., Cathcart M.K. The oxidation of lipoproteins by monocytes-macrophages. Biochemical and biological mechanisms. J. Biol. Chem. 274:1999;25959-25962.
90. Kuhn H., Chan L. The role of 15-lipoxygenase in atherogenesis pro- and antiatherogenic actions . Curr. Opin. Lipidol. 8:1997;111-117.
91. Patel, R. P.; Moellering, D.; Murphy-Ullrick, J.; Jo, H.; Beckman, J. S.; Darly-Usmar, V. M. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic. Biol. Med.28:1780-1794.
92. Heinecke J.W., Rosen H., Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 74:1984;1890-1894.
93. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a form recognized by the scavenger receptor. Arteriosclerosis. 6:1986;505-510.
94. Cathcart M.K., Morel D.W., Chisolm G.M. III. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. Leukoc. Biol. 38:1985;341-350.
95. Fox P.L., Mazumder B., Ehrenwald E., Mukhopadhyay C. Ceruloplasmin and cardiovascular disease. Free Radic. Biol. Med. 28:2000;1735-1744.
96. Calara F., Dimayuga P., Niemann A., Thyberg J., Diczfalusy U., Witztum J.L., Palinski W., Shah P.K., Cercek B., Nilsson J., Regnstrom J. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler. Thromb. Vasc. Biol. 18:1998;884-893.
97. Juul K., Nielsen L.B., Munkholm K., Stender S., Nordestgaard B.G. Oxidation of plasma low-density lipoprotein accelerates its accumulation and degradation in the arterial wall in vivo. Circulation. 94:1996;1698-1704.
98. Houglum K., Ramm G.A., Crawford D.H., Witztum J.L., Powell L.W., Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology. 26:1997;605-610.
99. Neale T.J., Ojha P.P., Exner M., Poczewski H., Ruger B., Witztum J.L., Davis P., Kerjaschki D. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J. Clin. Invest. 94:1994;1577-1584.
100. Freeman M., Ekkel Y., Rohrer L., Penman M., Freedman N.J., Chisolm G.M., Krieger M. Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells lipid droplet accumulation and nonreciprocal cross competition by acetylated and oxidized low density lipoprotein . Proc. Natl. Acad. Sci. USA. 88:1991;4931-4935.
101. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains a-helical and collagen-like coiled coils. Nature. 343:1990;532-534.
102. Rohrer L., Freeman M., Kodama T., Penman M., Krieger M. Coiled-coil fibrous domains mediate binding by the macrophage scavenger type II. Nature. 343:1990;570-572.
103. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:1993;11811-11816.
104. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269:1994;21003-21009.
105. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., Tanaka T., Miwa S., Katsura Y., Kita T., Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 386:1997;73-77.
106. Ramprasad M.P., Fischer W., Witztum J.L., Sambrano G.R., Quehenberger O., Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl. Acad. Sci. USA. 92:1995;9580-9584.
107. Parthasarathy S., Fong L.G., Otero D., Steinberg D. Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc. Natl. Acad. Sci. USA. 84:1987;537-540.
108. Bird D.A., Gillotte K.L., Horkko S., Friedman P., Dennis E.A., Witztum J.L., Steinberg D. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties implications with respect to macrophage recognition of apoptotic cells . Proc. Natl. Acad. Sci. USA. 96:1999;6347-6352.
109. Podrez E.A., Febbraio M., Sheibani N., Schmitt D., Silverstein R.L., Hajjar D.P., Cohen P.A., Frazier W.A., Hoff H.F., Hazen S.L. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J. Clin. Invest. 105:2000;1095-1108.
110. Boullier A., Gillotte K.L., Horkko S., Green S.R., Friedman P., Dennis E.A., Witztum J.L., Steinberg D., Quehenberger O. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 275:2000;9163-9169.
111. Horkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103:1999;117-128.
112. Terpstra V., Bird D.A., Steinberg D. Evidence that the lipid moiety of oxidized low density lipoprotein plays a role in its interaction with macrophage receptors. Proc. Natl. Acad. Sci. USA. 95:1998;1806-1811.
113. Steinberg D. Clinical trials of antioxidants in atherosclerosis are we doing the right thing? Lancet. 346:1995;36-38.
114. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
115. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 328:1993;1450-1456.
116. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 328:1993;1444-1449.
117. Ball R.Y., Carpenter K.L., Mitchinson M.J. What is the significance of ceroid in human atherosclerosis? Arch. Pathol. Lab. Med. 111:1987;1134-1140.
118. Brown A.J., Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 142:1999;1-28.
119. Heinecke J.W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol. 8:1997;268-274.
120. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S.W., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
121. Christen W.G., Gaziano J.M., Hennekens C.H. Design of physicians' health study II - a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann. Epidemiol. 10:2000;125-134.
122. Rimm E.B., Stampfer M.J. Antioxidants for vascular disease. Med. Clin. North Am. 84:2000;239-249.
123. Reaven P.D., Khouw A., Beltz W.F., Parthasarathy S., Witztum J.L. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler. Thromb. 13:1993;590-600.
124. Reaven P.D., Ferguson E., Navab M., Powell F.L. Susceptibility of human LDL to oxidative modification. Effects of variations in beta-carotene concentration and oxygen tension. Arterioscler. Thromb. 14:1994;1162-1169.
125. Dieber-Rotheneder M., Puhl H., Waeg G., Striegl G., Esterbauer H. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J. Lipid Res. 32:1991;1325-1332.
126. Pryor W.A. Vitamin E and heart disease basic science to clinical intervention trials . Free Radic. Biol. Med. 28:2000;141-164.
127. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N. Engl. J. Med. 342:2000;154-160.
128. Leppala J.M., Virtamo J., Fogelholm R., Huttunen J.K., Albanes D., Taylor P.R., Heinonen O.P. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler. Thromb. Vasc. Biol. 20:2000;230-235.
129. Tornwall M.E., Virtamo J., Haukka J.K., Aro A., Albanes D., Huttunen J.K. The effect of alpha-tocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. Atherosclerosis. 147:1999;193-197.
130. Teikari J.M., Laatikainen L., Rapola J.M., Virtamo J., Haukka J., Liesto K., Taylor P., Heinonen O.P. Retinal vascular changes following supplementation with alpha-tocopherol or beta-carotene. Acta Ophthalmol. Scand. 76:1998;68-73.
131. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 347:1996;781-786.
132. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354:447-455; 1999.
133. Thomas S.R., Stocker R. Molecular action of vitamin E in lipoprotein oxidation implications for atherosclerosis. Free Radic. Biol. Med. 28:2000;1795-1805.
134. Pryor W.A., Strickland T., Church D.F. Comparison of the efficiencies of several natural and synthetic antioxidants in aqueous sodium dodecyl sulfate micelle solutions. J. Am. Chem. Soc. 110:1988;2224-2229.